AMG-009|CAS 1027847-67-1|DC Chemicals

Cas No.:	1027847-67-1
Chemical Name:	4-4-(Butylamino)carbonyl-2-(2,4-dichlorophenyl)sulfonylaminophenoxy-3-methoxy-benzeneacetic Acid
Synonyms:	2-[4-[4-(butylcarbamoyl)-2-[(2,4-dichlorophenyl)sulfonylamino]phenoxy]-3-methoxyphenyl]acetic acid;AMG-009;AMG 009;83262TRK3S;2-(4-(4-(butylcarbamoyl)-2-((2,4-dichlorophenyl)sulfonamido)phenoxy)-3-methoxyphenyl)acetic acid;Benzeneacetic acid, 4-[4-[(butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-;Benzeneacetic acid, 4-[4-[(butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-;amg009;AKOS040741101;AKOS040741101;Q27269380;Q27269380;SCHEMBL6951622;SCHEMBL6951622;BDBM50302828;2-(4-(4-(butylcarbamoyl)-2-(2,4-dichlorophenylsulfonamido)phenoxy)-3-methoxyphenyl)acetic acid;BDBM50302828;UNII-83262TRK3S;2-(4-(4-(butylcarbamoyl)-2-(2,4-dichlorophenylsulfonamido)phenoxy)-3-methoxyphenyl)acetic acid;HY-19499;Benzeneacetic acid, 4-(4-((butylamino)carbonyl)-2-(((2,4-dichlorophenyl)sulfonyl)amino)phenoxy)-3-methoxy-;UNII-83262TRK3S;CHEMBL589973;HY-19499;EX-A4582;Benzeneacetic acid, 4-(4-((butylamino)carbonyl)-2-(((2,4-dichlorophenyl)sulfonyl)amino)phenoxy)-3-methoxy-;1027847-67-1;CRB84767;CHEMBL589973;AMG 009;;EX-A4582;GLXC-25371;1027847-67-1;DA-70760;CRB84767;CS-6808;AMG 009;;4-[4-[(Butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-benzeneaceticAcid;GLXC-25371;4-[4-[(Butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-benzeneacetic Acid;DA-70760;CS-6808;4-[4-[(Butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-benzeneaceticAcid;4-[4-[(Butylamino)carbonyl]-2-[[(2,4-dichlorophenyl)sulfonyl]amino]phenoxy]-3-methoxy-benzeneacetic Acid
SMILES:	ClC1C([H])=C(C([H])=C([H])C=1S(N([H])C1C([H])=C(C([H])=C([H])C=1OC1C([H])=C([H])C(C([H])([H])C(=O)O[H])=C([H])C=1OC([H])([H])[H])C(N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)(=O)=O)Cl
Formula:	C₂₆H₂₆Cl₂N₂O₇S
M.Wt:	581.4648
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.